TSX-V:KNE - TSX Venture Exchange - CA4838092084 - Common Stock - Currency: CAD
TSX-V:KNE (4/30/2025, 7:00:00 PM)
0.08
0 (0%)
The current stock price of KNE.CA is 0.08 CAD. In the past month the price decreased by -15.79%. In the past year, price decreased by -38.46%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EDT.CA | SPECTRAL MEDICAL INC | N/A | 228.10M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 196.82M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 179.78M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 90.74M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 65.22M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 13.24 | 61.70M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 61.62M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 51.14M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 50.90M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 35 | 49.36M | ||
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 22.71M | ||
CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 14.79M |
Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The firm is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The firm has a portfolio of biotechnologies, intellectual property (65 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research and acquired from research institutions. DispersinB, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of Kane Biotech Inc. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The firm's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.
KANE BIOTECH INC
290-100 Innovation Drive
Winnipeg MANITOBA R3T 2N2 CA
CEO: Marc Edwards
Employees: 0
Company Website: https://kanebiotech.com/
Investor Relations: http://ir.kanebiotech.com/
Phone: 12044531301
The current stock price of KNE.CA is 0.08 CAD.
The exchange symbol of KANE BIOTECH INC is KNE and it is listed on the TSX Venture Exchange exchange.
KNE.CA stock is listed on the TSX Venture Exchange exchange.
KANE BIOTECH INC (KNE.CA) has a market capitalization of 12.38M CAD. This makes KNE.CA a Nano Cap stock.
KANE BIOTECH INC (KNE.CA) currently has 0 employees.
KANE BIOTECH INC (KNE.CA) has a resistance level at 0.09. Check the full technical report for a detailed analysis of KNE.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KNE.CA does not pay a dividend.
KANE BIOTECH INC (KNE.CA) will report earnings on 2025-05-22.
The PE ratio for KANE BIOTECH INC (KNE.CA) is 8. This is based on the reported non-GAAP earnings per share of 0.01 and the current share price of 0.08 CAD. Check the full fundamental report for a full analysis of the valuation metrics for KNE.CA.
ChartMill assigns a fundamental rating of 2 / 10 to KNE.CA. KNE.CA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months KNE.CA reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS increased by 122.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 105.28% | ||
ROA | 56.72% | ||
ROE | N/A | ||
Debt/Equity | N/A |